Eleven Biotherapeutics, Inc. is a preclinical stage biopharmaceutical company engages in medical development. It involves in the management of proprietary protein engineering platform called AMP-Rx for the development and discovery of protein therapeutics to treat diseases of the eye. Through therapeutic approach, it focuses on structural biology of cytokines to design and generate product candidate called EBI-031, that targets Diabetic Macular Edema diseases. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
